ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences:

  • Financial Times Pharma and Biotech Summit in London

    Format: Industry Panel

    Date and Time: Wednesday, November 9th, 9:55 a.m. – 10:40 a.m. ET

    Conference link:
  • Credit Suisse Annual Healthcare Conference in Southern California

    Format: Fireside Chat

    Date and Time: Wednesday, November 9th, 4:35 p.m. – 6:35 p.m. ET

    Conference link:
  • HLTH in Las Vegas

    Format: Industry Panel

    Date and Time: Monday, November 14th, 7:20 p.m. - 8:00 p.m. ET

    Conference link:
  • Jefferies Healthcare Conference in London

    Format: Fireside Chat

    Date and Time: Wednesday, November 16th, 8:00 a.m. – 8:30 a.m. GMT

    Conference link:
  • Collaborating for Novel Solutions (CNS) Summit in Boca Raton, Florida

    Format: Keynote Industry Panel

    Date and Time: Saturday, November 19th, 12 p.m. – 12:30 p.m. ET

    Conference link:

Certain events will have archived webcasts available in the section of atai’s website at , where they will be available for up to 90 days.

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

Contact Information

Investor Contact:

Stephen Bardin

Chief Financial Officer

Email:

Media Contact:

Allan Malievsky

Senior Director of External Affairs

Email:  



EN
01/11/2022

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Reports Second Quarter 2025 Financial Results and R...

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects fo...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascam...

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpointInidascamine continues to exhibit a favorable safety and tolerability profileFull data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognif...

July 25, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces $50 Million Private Placement Financing

atai Life Sciences Announces $50 Million Private Placement Financing Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 NEW YORK and AMSTERDAM, July 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced it had entered into subscription agreements relating to the purchase of 18,264,840 ordinary...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences and Beckley Psytech Announce Positive Topline Resul...

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single doseBoth 8 mg and 12 mg single doses of BPL-003 showed statistically significant and clinically meaningful reductions in depressive symptoms at all time points of the study compared to a 0.3 mg low-dose active control out to Week 8BPL-003 was generally well-tolerated at all doses, with 99% of trea...

July 1, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences and Beckley Psytech to Combine Creating a Global Le...

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-...

June 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch